NLRP1 and Alzheimer disease: Inhibition of the inflammasome Nod-like receptor protein 1 (Nlrp1)18, Nlrp315, Casp115,19 or the inflammasome activator purinergic P2X7 receptor20, reduces inflammation, improves synaptic pathology, reduces Aβ accumulation and reverses cognitive deficits in AD mouse models.